Browse the evidence

Frequent eating out of home is negatively correlated with sleep duration and physical activity time.

Frequent eating out is linked to shorter sleep and less physical activity. If you eat out often, be aware that this may be part of a broader pattern of reduced self-care. Try to schedule sleep and exercise as non-negotiable appointments, even if it means preparing simpler meals at home.

Nudge techniques (environmental modifications influencing behavior) result in modest but significant weight loss, particularly in men with severe obesity.

Modify your environment to make healthy choices easier (e.g., keep healthy food visible, remove unhealthy food from sight). This is particularly effective for men with severe obesity.

Daily administration of 100 mg mirabegron (a selective β3-AR agonist) increases energy expenditure and skin temperature in humans without cardiovascular side effects, offering a pharmacological alternative to cold exposure for activating brown adipose tissue.

If you are looking to boost metabolic rate through medication, 100 mg of mirabegron daily has been shown in studies to increase energy expenditure and skin temperature without causing heart issues. This is a repurposed drug originally for bladder issues, but it targets fat-burning pathways. Note that higher doses (150-200mg) may cause heart rate and blood pressure increases, so 100mg is the identified safe effective dose in the cited research.

GLP-1 receptor agonists are cost-effective for expanding access to obesity treatment, particularly for patients ineligible for or hesitant about surgery, and can serve as a bridge to surgery or adjunct for post-surgical regain.

If you cannot have surgery due to health risks, insurance, or wait times, GLP-1 medications are a viable, evidence-based option. They can help you lose enough weight to become a surgical candidate or manage weight after surgery. However, be prepared for lifelong use to maintain results.

GLP-1 receptor agonists (GLP-1RAs) are perceived by current and past users as safe and effective for weight loss, with users strongly disagreeing that risks outweigh benefits, whereas non-users exhibit significant skepticism regarding safety and efficacy.

If you are considering GLP-1RAs, be aware that skepticism about safety and cost are common barriers, especially if you haven't used them. However, data from current and past users shows they strongly disagree that risks outweigh benefits and highly recommend the medication. Consult a healthcare provider to address specific safety concerns and cost barriers, as user experience often contradicts public skepticism.

Neuromuscular electrical stimulation-based resistance training (NMES-RT) is the most robust and consistent intervention for increasing skeletal muscle mass in the paralyzed limbs of persons with chronic, motor complete spinal cord injury.

For individuals with chronic, complete spinal cord injury aiming to increase muscle mass, NMES-based resistance training (specifically the Dudley Protocol) is the most effective current strategy. This involves performing 3-4 sets of 10 electrically stimulated knee extensions twice weekly with progressive resistance. While other methods like FES cycling or pharmacological treatments exist, NMES-RT yields the largest and most consistent muscle growth, particularly in the quadriceps.

Gut microbiota composition, specifically the abundance of Blautia and Firmicutes, modulates lipid metabolism outcomes in response to personalized nutrition, with risk genotype carriers showing increased Blautia abundance associated with improved HDL and LDL levels.

Your gut bacteria play a role in how your body processes fats and cholesterol, especially if you have the FTO risk genotype. A personalized diet that increases microbial diversity (like the PN intervention did) may help improve your lipid profile by fostering beneficial bacteria like Blautia.

Isocalorically substituting 5% of total energy intake from carbohydrates with polyunsaturated fatty acids (PUFA), specifically n-3 and n-6, or plant-based monounsaturated fatty acids (MUFA) is associated with a statistically significant reduction in all-cause mortality risk.

To potentially lower your risk of all-cause mortality, focus on swapping the energy from carbohydrates for healthy fats. Specifically, aim to replace 5% of your total daily energy from carbs with polyunsaturated fats (like those in nuts, seeds, and fish) or plant-based monounsaturated fats (like olive oil). This swap is associated with a lower risk of death, according to a large network meta-analysis of observational studies.

Isocalorically substituting 5% of total energy intake from Saturated Fatty Acids (SFA) and Trans-Fatty Acids (TFA) with Polyunsaturated Fatty Acids (PUFA) or Plant-based Monounsaturated Fatty Acids (MUFA) is associated with a statistically significant reduction in all-cause mortality risk.

To potentially lower your risk of all-cause mortality, focus on swapping the energy from Saturated Fats (SFA) and Trans Fats (TFA) for healthier fats. Specifically, aim to replace 5% of your total daily energy from SFA/TFA with Polyunsaturated Fats (PUFA, found in nuts, seeds, fish) or Plant-based Monounsaturated Fats (MUFA, found in olive oil). This swap is associated with a lower risk of death, according to a large network meta-analysis of observational studies.

Isocalorically substituting 5% of total energy intake from Animal Protein with Plant Protein is associated with a statistically significant reduction in all-cause mortality risk.

To potentially lower your risk of all-cause mortality, focus on swapping the energy from Animal Protein for Plant Protein. Specifically, aim to replace 5% of your total daily energy from animal sources (meat, dairy, eggs) with plant sources (beans, lentils, nuts, seeds). This swap is associated with a lower risk of death, according to a large network meta-analysis of observational studies.

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) significantly reduce rheumatoid arthritis (RA) disease activity and pain in patients with RA and overweight or obesity, independent of the magnitude of weight loss.

If you have Rheumatoid Arthritis and are overweight, GLP-1 medications (like Ozempic or Mounjaro) may help reduce your joint pain and disease activity, not just help you lose weight. This benefit appears to come from the drug's direct effect on inflammation, not just the weight loss itself. Be aware that stomach side effects are common and insurance coverage can be a hurdle, but the potential for improved RA control is a significant clinical benefit to discuss with your rheumatologist.

Preventing 'weight creep' (0.5-1 kg/year gain) through low-intensity lifestyle interventions is a more achievable and effective strategy for OA management than focusing solely on significant weight loss in already obese individuals.

Focus on preventing the slow, yearly weight gain (0.5-1kg) rather than just trying to lose large amounts of weight. Make small, sustainable changes to your diet and activity (e.g., slightly less food, slightly more movement) to create a small energy deficit. This is easier to maintain and significantly reduces the risk of needing knee replacement surgery.

Current dietary guidelines (RDA of 0.8 g/kg) may be insufficient for older adults to prevent muscle loss, but exceeding this amount alone does not significantly improve strength or performance without resistance training.

As you age, you might need more protein to maintain muscle, but just eating more protein won't make you stronger. You must combine adequate protein with resistance training to preserve strength and function. Exceeding recommended amounts without exercise offers little extra benefit.

Beta-alanine supplementation improves specific military occupational performance tasks (casualty carry, cognitive tests) and reduces inflammation (IL-10) but does not improve general strength or sprint performance.

Take 6g of beta-alanine daily for 30 days if your role involves sustained carrying or cognitive tasks under fatigue. It will not make you stronger or faster in sprints, but it may help you carry casualties and stay sharp.

Beetroot juice supplementation improves physiological efficiency (heart rate recovery, step test scores) at altitude but does not significantly change performance at sea level.

If you are operating at high altitude, consuming beetroot juice (high nitrate) can help maintain performance and heart rate recovery. It may not provide benefits at sea level.

GLP-1 receptor agonists (GLP-1RAs) provide modest antidepressant effects and reduce binge eating behaviors, but their impact on suicidality remains uncertain and potentially elevated in high-risk subgroups.

GLP-1 medications like semaglutide and liraglutide may help with mild depression and binge eating, especially if you have diabetes or obesity. However, if you have a history of severe mental health issues or take other psychiatric meds, monitor your mood closely as there may be a small increased risk of suicidal thoughts. The mental health benefits appear to come from direct brain effects, not just weight loss.

Prediabetic patients with obesity require comprehensive management of metabolic complications and specific prevention strategies to avoid progression to overt diabetes.

If you have prediabetes and are overweight, you cannot ignore it. You must actively manage your metabolic health through lifestyle changes and medical guidance to prevent full-blown diabetes.

High-protein provision (≥1.2 g/kg/day) combined with exercise therapy improves muscle mass and functional independence (ADL) in ICU survivors, but does not significantly improve quality of life (QoL) or mortality compared to standard care.

For ICU survivors, combining high protein intake (aiming for >1.2 g/kg/day) with early, structured exercise (including electrical stimulation if needed) can help preserve muscle and improve daily independence. However, this does not guarantee better quality of life or survival, and success depends heavily on actually delivering the prescribed protein, which is often difficult due to gut issues during critical illness.

Immersive Virtual Reality (IVR) cable resistance exergaming elicits muscle activation patterns and metabolic demands comparable to traditional resistance training while significantly reducing perceived exertion through dissociative attention.

If you struggle with resistance training because it feels too hard or boring, try an IVR system with adaptive resistance (like Black Box VR). It automatically adjusts weights to keep you near muscle failure, which builds strength and muscle effectively. The game environment distracts you from the fatigue, making high-intensity workouts feel more enjoyable and sustainable than traditional gym routines.

Combining Duodenal Mucosal Ablation (DMR) or Electroporation (ReCET) with GLP-1 receptor agonists (like Liraglutide or Semaglutide) can enable a majority of insulin-requiring T2D patients to eliminate exogenous insulin.

If you have Type 2 Diabetes and require insulin, ask your doctor about combining endoscopic procedures (like DMR or ReCET) with GLP-1 medications (like Semaglutide or Liraglutide). This combination has shown high success rates (up to 86% in small studies) in helping patients stop taking insulin. While it involves both a procedure and medication, the goal is to achieve insulin independence and better long-term control. This approach is still emerging, so discuss the risks and benefits with a specialist.

Higher Body Mass Index (BMI) is significantly correlated with lower VO2 max in martial arts athletes, indicating that increased body mass is associated with reduced aerobic capacity.

For martial arts athletes, maintaining a healthy BMI is crucial for maximizing aerobic capacity (VO2 max). If your BMI is high, it may be limiting your endurance. Focus on nutritional periodization and body composition management to improve your VO2 max, which is a key determinant of performance in sports like Karate, Judo, and Kempo.

Preoperative optimization with GLP-1 agonists (specifically semaglutide 2.4 mg/week) enables patients with severe obesity (BMI ≥ 35 kg/m²) to achieve target BMI ≤ 35 kg/m², making them eligible for complex abdominal wall repair.

If you have severe obesity and need complex abdominal wall surgery, standard diet and exercise often fail to lower your BMI enough for safe surgery. Using GLP-1 agonists (like semaglutide) for about 8 months can help you lose enough weight (average 11.3%) to meet the safety threshold (BMI ≤ 35) for the procedure. This makes you eligible for surgery that might otherwise be denied or deemed too risky.

In adults with Type 1 Diabetes (T1D) and obesity (BMI ≥27 kg/m²), 12 months of treatment with GLP-1 receptor agonists (tirzepatide, semaglutide, or liraglutide) produces significant weight loss (7.1%–10.9%) without increasing the risk of severe hypoglycemia or diabetic ketoacidosis (DKA).

If you have Type 1 Diabetes and obesity, GLP-1 based medications (tirzepatide, semaglutide, or liraglutide) can help you lose significant weight (7-11%) over a year without increasing your risk of dangerous low blood sugar or DKA, provided your insulin regimen is stable. These drugs also modestly improve blood sugar control and reduce insulin needs.

Among GLP-1/GIP agonists used in Type 1 Diabetes, tirzepatide produces significantly greater weight loss (10.9%) compared to semaglutide (9.9%) and liraglutide (7.1%).

If you have Type 1 Diabetes and obesity, tirzepatide appears to offer the highest weight loss potential (approx. 11%) compared to semaglutide (approx. 10%) and liraglutide (approx. 7%) over 12 months, though all are effective.